Literature DB >> 21512575

Dysbindin-1 and NRG-1 gene expression in immortalized lymphocytes from patients with schizophrenia.

Hidenaga Yamamori1, Ryota Hashimoto, Louise Verrall, Yuka Yasuda, Kazutaka Ohi, Motoyuki Fukumoto, Satomi Umeda-Yano, Akira Ito, Masatoshi Takeda.   

Abstract

The dysbindin-1 and neuregulin-1 (NRG-1) genes are related to schizophrenia. Expression studies in postmortem brains have revealed lower expression of dysbindin-1 and higher expression of NRG-1 in brain tissue from subjects with schizophrenia. In addition to the difficulty of sampling, the use of postmortem brain tissues is not ideal because these tissues are heterogeneous with respect to biochemical parameters, lifetime history of medications and physiological status at the time of death. In contrast, medication and environmental influences that could mask the genetic basis of differences in RNA expression are removed in immortalized lymphocytes by culturing. Only a few microarray analysis studies using immortalized lymphocytes in schizophrenia have been reported, and whether immortalized lymphocytes are an appropriate alternative to neuronal tissue remains controversial. In this study, we measured the mRNA expression levels of dysbindin-1, NRG-1 and two other genes (NPY1R and GNAO1) in immortalized lymphocytes from 45 patients with schizophrenia and 45 controls using real-time quantitative reverse transcriptase-PCR. No difference was observed between patients and controls with respect to the expression of dysbindin-1, NRG-1, NPY1R or GNAO1 gene. Our findings suggest that the gene expression profile of immortalized lymphocyte from schizophrenic patients is different from that in postmortem brain tissue at least with respect to the dysbindin-1 and NRG-1 genes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512575     DOI: 10.1038/jhg.2011.40

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  10 in total

1.  Altered gene expression in lymphoblastoid cell lines after subculture.

Authors:  Michihiro Toritsuka; Manabu Makinodan; Takahira Yamauchi; Yasunori Yamashita; Daisuke Ikawa; Takashi Komori; Sohei Kimoto; Kaori Hamano-Iwasa; Hideo Matsuzaki; Toshifumi Kishimoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-06-12       Impact factor: 2.416

Review 2.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

3.  Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis.

Authors:  Gursharan Chana; Chad A Bousman; Tammie T Money; Andrew Gibbons; Piers Gillett; Brian Dean; Ian P Everall
Journal:  Front Cell Neurosci       Date:  2013-06-26       Impact factor: 5.505

Review 4.  Modeling psychiatric disorders through reprogramming.

Authors:  Kristen J Brennand; Fred H Gage
Journal:  Dis Model Mech       Date:  2011-10-04       Impact factor: 5.758

5.  Behavioral characterization of mice overexpressing human dysbindin-1.

Authors:  Norihito Shintani; Yusuke Onaka; Ryota Hashimoto; Hironori Takamura; Tsuyoshi Nagata; Satomi Umeda-Yano; Akihiro Mouri; Takayoshi Mamiya; Ryota Haba; Shinsuke Matsuzaki; Taiichi Katayama; Hidenaga Yamamori; Takanobu Nakazawa; Kazuki Nagayasu; Yukio Ago; Yuki Yagasaki; Toshitaka Nabeshima; Masatoshi Takeda; Hitoshi Hashimoto
Journal:  Mol Brain       Date:  2014-10-09       Impact factor: 4.041

6.  Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits.

Authors:  Vinita Jagannath; Anastasia Theodoridou; Miriam Gerstenberg; Maurizia Franscini; Karsten Heekeren; Christoph U Correll; Wulf Rössler; Edna Grünblatt; Susanne Walitza
Journal:  Front Psychiatry       Date:  2017-12-20       Impact factor: 4.157

7.  Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients.

Authors:  Md Shaki Mostaid; Ting Ting Lee; Gursharan Chana; Suresh Sundram; Cynthia Shannon Weickert; Christos Pantelis; Ian Everall; Chad Bousman
Journal:  Transl Psychiatry       Date:  2017-12-11       Impact factor: 6.222

8.  Emerging roles of ARHGAP33 in intracellular trafficking of TrkB and pathophysiology of neuropsychiatric disorders.

Authors:  Takanobu Nakazawa; Ryota Hashimoto; Kazuto Sakoori; Yuki Sugaya; Asami Tanimura; Yuki Hashimotodani; Kazutaka Ohi; Hidenaga Yamamori; Yuka Yasuda; Satomi Umeda-Yano; Yuji Kiyama; Kohtarou Konno; Takeshi Inoue; Kazumasa Yokoyama; Takafumi Inoue; Shusuke Numata; Tohru Ohnuma; Nakao Iwata; Norio Ozaki; Hitoshi Hashimoto; Masahiko Watanabe; Toshiya Manabe; Tadashi Yamamoto; Masatoshi Takeda; Masanobu Kano
Journal:  Nat Commun       Date:  2016-02-03       Impact factor: 14.919

9.  Increased dysbindin-1B isoform expression in schizophrenia and its propensity in aggresome formation.

Authors:  Yiliang Xu; Yuhui Sun; Haihong Ye; Li Zhu; Jianghong Liu; Xiaofeng Wu; Le Wang; Tingting He; Yan Shen; Jane Y Wu; Qi Xu
Journal:  Cell Discov       Date:  2015-11-10       Impact factor: 10.849

10.  Antipsychotic drugs increase Neuregulin1β1 serum levels in first-episode drug-naïve patients and chronic schizophrenia with suggestions for improving the treatment of psychotic symptoms.

Authors:  Haidong Yang; Wen Pan; Wenhuan Xiao; Man Yang; Jianchun Xu; Jin Li; Xiaobin Zhang
Journal:  BMC Psychiatry       Date:  2022-03-25       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.